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Abstract
In the previous issue of Breast Cancer Research, Broeks and
collaborators present the results of a study suggesting that
germline mutations in BRCA1,  BRCA2,  ATM or  CHEK2 may
double the risk of radiation-induced contralateral breast cancer
following radiotherapy for a first breast cancer. The assocation
appeared to be strongest among women who were below the age
of 40 at the time of their first breast cancer and among women
who developed their second cancer 5 years or more after the first.
While there were a number of methodological issues that might
limit the conclusions drawn from this paper, this is one of several
recent studies suggesting that carriers of pathogenic alleles in
DNA repair and damage recognition genes may have an increased
risk of breast cancer following exposure to ionising radiation, even
at low doses. This finding has important implications for the
protection of breast cancer patients and their close relatives. If
confirmed, mutation carriers may wish to consider alternatives to X-
ray for diagnostic purposes. The need for tailored cancer treatment
strategies in carriers should also be evaluated carefully.
Breast cancer (BC) is the most common cancer and one of
the leading causes of death among women worldwide, with
nearly 1,000,000 new cases per year [1]. Known risk factors
include genetic susceptibility and exposure to ionising
radiation [2]. The risks are highest among women exposed in
childhood and adolescence and are among the highest
known radiation-related risks for any cancer type [3].
Associations have been reported between inherited BC and
pathogenic alleles in ten different genes involved in pathways
critical for genomic integrity [4]. BRCA1 and BRCA2 muta-
tions confer very high risks of breast and ovarian cancer. p53
and PTEN mutations lead to very high BC risks associated
with rare cancer syndromes. Mutations in CHEK2,  ATM,
NBS1, RAD50, BRIP1, and PALB2 are associated with at
least a doubling of BC risk. Because many of these genes are
specifically implicated in the response to ionising radiation,
women who carry pathogenic alleles in these genes might be
more sensitive to radiation-induced BC than non-carriers, as
suggested by recent studies [5,6]
In the previous issue of Breast Cancer Research, Broeks and
collaborators [7] present results suggesting that pathogenic
alleles in four specific DNA repair and damage recognition
genes increase the risk of radiation-induced contralateral BC
following radiotherapy for a first BC.
The study used a case-only design and included 247 cases
of contralateral BC diagnosed at two of the main cancer
treatment institutions in the Netherlands among women who
had a first BC before age 50 in the period 1966 to 2000.
Overall, 21% of cases carried a pathogenic allele in BRCA1,
BRCA2,  CHEK2 or  ATM. The percentages were 24.3%
among women who received radiation therapy for their first
cancer (169) and 12.8% among those who did not (78). The
odds ratio (OR) of developing contralateral BC following
radiation therapy was 2.18 (95% confidence interval (CI)
1.03-4.62) in women carrying a pathogenic allele compared
to women without. The assocation appeared to be strongest
among women aged less than 40 at the time of their first BC
(OR 2.77, 95%CI 0.74-10.39) and among women who
developed their second cancer 5 years or more after the first
(OR 2.51, 95%CI 1.03-6.10). The OR appeared to be lowest
for mutations in BRCA1 and highest for mutations in CHEK2,
although these results were based on small numbers of
cases and are not statistically significantly different.
In interpreting the results of this study, a number of methodo-
logical issues must be kept in mind. Firstly, because of the
techniques used for the screening of BRCA1 and BRCA2, a
number of sequence variants will have been missed,
disproportionately missense substitutions and particularly in
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BRCA2. Secondly, a full screen was not carried out for
CHEK2. Whilst 1100delC appears to be the major patho-
genic allele in some European populations (for example, the
UK), in others (for example, Poland) CHEK2 harbours
additional pathogenic alleles with appreciable frequencies.
We do not know where in this spectrum the population of the
Netherlands falls because the number of Dutch subjects who
have been completely mutation screened is quite small [8].
The proportion of carriers of deleterious mutations is,
therefore, likely to be underestimated in this study. The
impact of this is unclear; if these other mutations do not
confer an increased risk of radiation-induced BC, one could
expect a reduction in the OR. If, on the other hand, the effect
is greater than for those studied, the OR may be under-
estimated.
Of the four genes screened, the analysis of ATM was the
most complete. Perhaps in order to make the ATM data more
compatible with the limited sensitivity of the mutation screen-
ing for the other genes, the authors excluded from their risk
calculations the ATM missense substitutions detected in this
cohort. In a simultaneously published paper on the same
study subjects, ATM missense substitution carriers appear to
have a shorter latency of contralateral BC following radiation
therapy than non-carriers [9], thus lending support to the
hypothesis that rare missense sequence variants in ATM may
also influence the risk of radiation-induced BC.
Another issue in the interpretation of these findings is the
possibility that the choice of treatment protocols might be
biased by clinico-pathological factors related to carrier status
(even when it is unknown). For example, patients with
estrogen receptor negative basal tumours may have received
a more aggressive therapy because of their poorer prognosis,
and it is known that BRCA1 carriers present with a dispro-
portionate frequency of estrogen receptor negative basal
tumours [10]. The authors report, however, that adjustment of
the analyses for stage, size of tumour and lymph node
involvement had little effect on the results (resulting ORs not
shown).
It has been known for almost a decade that, after a first
diagnosis of BC, BRCA1 and BRCA2 mutation carriers have
a very high risk of developing a second breast tumour [11-
13]. Because of the success rates of treatment, increasing
numbers of women are surviving their first tumour. Five-year
survival rates are about 75% in Europe [14]. The risk of
developing a therapy-related tumour is, therefore, of increas-
ing concern, both from the public health and patient manage-
ment perspectives.
The GENE-RAD-RISK project, a large European study, is
currently underway to evaluate whether carriers of pathogenic
alleles in DNA repair and damage recognition genes may
confer an increased risk of breast cancer following medical
irradiation [15]. If, as suggested in this paper, the treatment is
exacerbating the already disproportionate risk of second
primary BC in mutation carriers, treatment protocols
designed to minimize the risk of a second cancer need to be
investigated in careful clinical studies.
Conclusions
While results of this and other recent studies still need to be
confirmed, there is increasing evidence that carriers of path-
ogenic alleles in DNA repair and damage recognition genes
may have an increased risk of BC following exposure to
ionising radiation, even at low doses. This finding has
important implications for the protection of patients and their
close relatives.
If confirmed, mutation carriers may wish to consider
alternatives to X-ray for diagnostic purposes, such as
magnetic resonance imaging (MRI). The need for tailored
cancer treatment strategies in carriers should also be
evaluated carefully.
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